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ABSTRACT
OBJECTIVE
To assess the association between covid-19 vaccines 
and risk of thrombocytopenia and thromboembolic 
events in England among adults.
DESIGN
Self-controlled case series study using national data 
on covid-19 vaccination and hospital admissions.
SETTING
Patient level data were obtained for approximately 
30 million people vaccinated in England between 1 
December 2020 and 24 April 2021. Electronic health 
records were linked with death data from the Office for 
National Statistics, SARS-CoV-2 positive test data, and 
hospital admission data from the United Kingdom’s 
health service (NHS).
PARTICIPANTS
29 121 633 people were vaccinated with first doses 
(19 608 008 with Oxford-AstraZeneca (ChAdOx1 nCoV-
19) and 9 513 625 with Pfizer-BioNTech (BNT162b2 
mRNA)) and 1 758 095 people had a positive SARS-
CoV-2 test. People aged ≥16 years who had first doses 
of the ChAdOx1 nCoV-19 or BNT162b2 mRNA vaccines 
and any outcome of interest were included in the 
study.
MAIN OUTCOME MEASURES
The primary outcomes were hospital admission or 
death associated with thrombocytopenia, venous 
thromboembolism, and arterial thromboembolism 
within 28 days of three exposures: first dose of the 
ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 
mRNA vaccine; and a SARS-CoV-2 positive test. 
Secondary outcomes were subsets of the primary 
outcomes: cerebral venous sinus thrombosis (CVST), 
ischaemic stroke, myocardial infarction, and other 
rare arterial thrombotic events.
RESULTS
The study found increased risk of thrombocytopenia 
after ChAdOx1 nCoV-19 vaccination (incidence rate 
ratio 1.33, 95% confidence interval 1.19 to 1.47 at 
8-14 days) and after a positive SARS-CoV-2 test (5.27, 
4.34 to 6.40 at 8-14 days); increased risk of venous 
thromboembolism after ChAdOx1 nCoV-19 vaccination 
(1.10, 1.02 to 1.18 at 8-14 days) and after SARS-
CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); 
and increased risk of arterial thromboembolism after 
BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 
15-21 days) and after SARS-CoV-2 infection (2.02, 
1.82 to 2.24 at 15-21 days). Secondary analyses 
found increased risk of CVST after ChAdOx1 nCoV-19 
vaccination (4.01, 2.08 to 7.71 at 8-14 days), after 
BNT162b2 mRNA vaccination (3.58, 1.39 to 9.27 at 
15-21 days), and after a positive SARS-CoV-2 test; 
increased risk of ischaemic stroke after BNT162b2 
mRNA vaccination (1.12, 1.04 to 1.20 at 15-21 days) 
and after a positive SARS-CoV-2 test; and increased 
risk of other rare arterial thrombotic events after 
ChAdOx1 nCoV-19 vaccination (1.21, 1.02 to 1.43 at 
8-14 days) and after a positive SARS-CoV-2 test.
CONCLUSION
Increased risks of haematological and vascular events 
that led to hospital admission or death were observed 
for short time intervals after first doses of the 
ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The 
risks of most of these events were substantially higher 
and more prolonged after SARS-CoV-2 infection than 
after vaccination in the same population.
Introduction
Covid-19 vaccines have been tested in randomised 
clinical trials1-3 that are designed to establish efficacy 
and safety, but insufficiently powered to detect rare 
adverse events. If a new vaccine has a serious adverse 
profile (even if the risk is rare), then a risk-benefit 
evaluation could lead to withdrawal of the vaccine or 
restrictions on its use in the interests of public safety. 
These risks, however, need to be balanced against the 
risks of covid-19 itself leading to adverse events and 
death.4 Safety evaluation is particularly important 
when vaccine development has been accelerated, 
the vaccines are new, and when rapid worldwide 
deployment of covid-19 vaccines has occurred, with 
1.43 billion doses already administered worldwide.5
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Rare thrombocytopenia and thromboembolic events have occurred after covid-19 
vaccination
After these rare events, several countries restricted the use of the ChAdOx1 
nCoV-19 (Oxford-AstraZeneca) vaccine
WHAT THIS STUDY ADDS
Increased risk of thrombocytopenia, venous thromboembolism, and other rare 
arterial thrombotic events were found after a first dose of the ChAdOx1 nCoV-19 
vaccine and of arterial thromboembolism and ischaemic stroke after a first dose 
of the BNT162b2 (Pfizer-BioNTech) vaccine
Increased risk of cerebral venous sinus thrombosis was found after a first dose of 
both vaccines—a week later with BNT162b2 than with ChAdOx1 nCoV-19
The risks of these outcomes after vaccination were much lower than those 
associated with SARS-CoV-2 infection in the same population
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Recently, thrombocytopenia and rare thrombo-
embolic events after the ChAdOx1 nCoV-19 (Oxford-
AstraZeneca) vaccine have been reported in Denmark, 
Norway,6 7 Germany, Austria,8 and the United 
Kingdom.9 This prompted several countries to limit the 
use of ChAdOx1 nCoV-19 on the basis that the benefits 
might not outweigh the risks.8-11 The United States 
has reported similar events associated with the Ad26.
COV2-S (recombinant) Janssen vaccine, resulting in a 
pause in its roll-out.12
The situation is further complicated by evidence on 
the associations between SARS-CoV-2 infection and 
thromboses.4 A US study estimated that the risk of 
cerebral venous sinus thrombosis (CVST) associated 
with SARS-CoV-2 infection is approximately seven 
times greater than that associated with the BNT162b2 
mRNA (Pfizer-BioNTech) or mRNA-1273 (Moderna) 
covid-19 vaccines.13 Direct comparisons between these 
vaccines and the ChAdOx1 nCoV-19 vaccine were not 
possible because the ChAdOx1 nCoV-19 vaccine is not 
used in the US. Evaluation of the safety of new vaccines 
relies on case reports or series, and analyses of large 
scale health data. While informative, case reports are 
limited by small numbers, and potential selection, 
recall, and recording biases. In contrast, routinely 
collected electronic health data contain recording of 
the exposure, outcomes, and confounders, and provide 
a rich source of data to enable the robust evaluation of 
rare vaccine safety events.14
We evaluated the short term risks of thrombo-
cytopenia, venous thromboembolism, and arterial 
thromboembolism associated with the first dose of 
the ChAdOx1 nCoV-19 and BNT162b2 vaccines, or 
a SARS-CoV-2 positive test in England between 1 
December 2020 and 24 April 2021. We also evaluated 
the risk of prespecified secondary outcomes of interest, 
namely CVST, ischaemic stroke, myocardial infarction, 
and other rare arterial thrombotic events according to 
a prespecified protocol.15
Methods
Study design and period
We undertook a self-controlled case series from 1 
December 2020 to 24 April 2021 (the latest date for 
which outcome data were available) to examine the 
associations between ChAdOx1 nCoV-19 or BNT162b2 
mRNA vaccines and thrombotic events during the 
ongoing covid-19 vaccination programme in England. 
We also investigated the association between a SARS-
CoV-2 positive test and the thrombotic events of 
interest among the same vaccinated population.
The self-controlled case series was originally 
developed to assess risks of adverse events to 
vaccination.16 The case series determines the relative 
incidence of the outcome of interest for exposed time 
periods (eg, after vaccination or SARS-CoV-2 infection) 
compared with unexposed baseline periods in people 
with the outcome of interest (see supplementary fig 1). 
Inference is within people and therefore this implicitly 
controls for all covariates that remain constant during 
the study period. We selected patients with each 
outcome during the study period and determined dates 
when they had the vaccine or tested positive for SARS-
CoV-2. Separate analyses were carried out for each 
outcome of interest.
Data sources
We used the National Immunisation Management 
System register of covid-19 vaccination to identify 
vaccine exposure, which includes vaccine type, 
date, and doses for all people vaccinated in England. 
We linked individual level data to national data for 
mortality, hospital admissions, and SARS-CoV-2 
infection. Linkages are conducted to protect patient 
anonymity because the hashed ID used to link 
patients cannot be reversed. Vaccine and SARS-
CoV-2 positive test data were available until 24 April 
2021. Hospital admission data were obtained from 
two sources: Hospital Episode Statistics (up to 31 
March 2021), which includes any admission, and 
Secondary Users Service (up to 24 April 2021), which 
includes only admissions with an outcome (death or 
discharge).
We used the QResearch database of 12 million 
patients linked to the above dataset to calculate 
background incidence rates for each outcome 
before the pandemic (2015-19). QResearch includes 
demographic, clinical, and drug data, and is used for 
clinical17 18 and drug safety research.19 20 QResearch 
is one of the largest and most representative primary 
care research databases nationally,21 covering 
approximately 20% of the population of England.
Visual Abstract Covid-19 and adverse events
aer vaccination and SARS-CoV- infection
Self-controlled 
case seriesStudy design
Compared exposed with unexposed
periods in the same patient
Population 29.1 million people vaccinated 
with first doses in England
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Increased risks of some adverse thrombotic events leading to 
hospital admission or death were observed in the  days aer first 
doses of vaccines. The risks of most of these events were 
substantially higher and more prolonged aer SARS-CoV- infection
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Inclusion criteria
We included all people aged ≥16 years who had first 
doses of the ChAdOx1 nCoV-19 or BNT162b2 mRNA 
vaccines and any outcome of interest. We excluded 
people who received the mRNA-1273 (Moderna) 
vaccine because of very small numbers. We used the 
first event in the study period and excluded patients 
from the analysis of each outcome if they had a hospital 
admission for the same event in the two years before 
the start of the study period.
Exposure
Our main exposures were the first dose of the ChAdOx1 
nCoV-19 or the BNT162b2 mRNA vaccine. We censored 
people on the earliest of the following: date of their 
second dose, date of death, or study end date (24 April 
2021). Our secondary exposure was a positive SARS-
CoV-2 test result, using the first date of a positive test 
(not the date of reporting) as the exposure date. We 
defined the exposure risk intervals as the following 
prespecified time periods: 0, 1-7, 8-14, 15-21, and 
22-28 days after each exposure date (vaccination 
date or date of positive SARS-CoV-2 test). Multiple 
risk intervals were used to differentiate between acute 
and non-acute phases after vaccination. The baseline 
period (without exposure) was defined as any time 
between 1 December 2020 and 29 days before the 
exposure date, and from 29 days after the exposure 
date until 24 April 2021 or the censored date if earlier. 
A pre-risk interval of 1-28 days before each exposure 
date was included to deal with possible bias that might 
arise if the occurrence of the outcome temporarily 
influenced the likelihood of exposure.22 Histograms 
of the data by interval between vaccination and event 
day are shown in supplementary figure 2a. The graphs 
show a drop of hospital admissions or deaths for each 
outcome about 28 days before vaccination, hence the 
choice of the pre-risk period. Hospital admissions for 
the event of interest are probably the trigger for the 
covid-19 test. Such events might be caused by SARS-
CoV-2 infection, but the reverse causality involved in 
their detection induces bias. To reduce the bias, which 
could overestimate or underestimate the effect of 
infection, we decided to allocate day 0 to a risk period 
on its own.23
Outcomes
Our three composite primary outcomes were hospital 
admission or death associated with thrombo-
cytopenia, venous thromboembolism, and arterial 
thromboembolism. Our prespecified secondary 
outcomes were subsets of the primary outcomes: 
CVST, ischaemic stroke, myocardial infarction, 
and other rare arterial thrombotic events. Hospital 
inpatient admissions from 1 December 2020 
to 24 April 2021 with an ICD-10 (International 
Classification of Diseases version 10) diagnosis code 
in their first 13 diagnoses fields that indicated the 
outcome of interest were identified in the Hospital 
Episode Statistics and Secondary Users Service 
databases. Supplementary table 1 gives a list of 
ICD-10 codes and groupings for each outcome. We 
used the earliest date of hospital admission or date 
of death for the relevant event as the event date. 
Cause of death in the UK is assessed by the medical 
practitioner who attended the patient during their 
last illness, and if not seen in the preceding 14 
days, the cause is determined by a coroner based on 
assessment of medical evidence.
Statistical analysis
We described the characteristics of each cohort 
(patients who had been vaccinated with the outcomes 
of interest) in terms of age, sex, and ethnicity. The 
self-controlled case series models were fitted using a 
conditional Poisson regression model with an offset 
for the length of the risk period. Incidence rate ratios, 
the relative rate of hospital admissions or deaths due 
to each outcome of interest in risk periods relative to 
baseline periods, and their 95% confidence intervals 
were estimated using each model. Exposure terms for 
both vaccines and for infection with SARS-CoV-2 were 
included in the same model. To account for temporal 
changes in background rates, we divided the study 
period into weekly blocks starting on 1 December 2020 
and adjusted for these changes as discrete covariates 
in the analysis. We used Wald tests to compare risks 
associated with ChAdOx1 nCoV-19 and BNT162b2 
mRNA vaccines. We investigated whether the 
associations between vaccine exposures and outcomes 
are sex or age dependent by running the analyses in 
separate subgroups by sex and age group (younger or 
older than 50 years).
Sensitivity analyses
We conducted six sensitivity analyses: (1) excluding 
those who died from the outcome; (2) restricting 
analysis to the period after vaccination or after a SARS-
CoV-2 positive test, without censoring at death; (3) 
censoring at 12 weeks after vaccination; (4) censoring 
on 10 March 2021; (5) restricting the study period 
until 31 March 2021; and (6) restricting the analysis 
to patients who had their vaccination after 1 January 
2021. The first two analyses tested the assumption 
that the occurrence of an outcome event did not 
influence the probability of subsequent exposures, 
such as through death.22 The third analysis tested the 
sensitivity to our approach of censoring patients at the 
time of the second dose (to avoid contamination of 
baseline time). The additional censoring at 12 weeks 
after the first dose of vaccine was used because this is 
the recommended time for a second dose in the UK. 
Concerns over CVST and blood clots were raised first in 
Europe around 10 March 2021, and so we censored on 
this date for the fourth sensitivity analysis; this allowed 
us to include only time unaffected by any notoriety 
bias (because of media attention, thrombotic events 
might have been more likely to be reported on death 
certificates or hospital admission records if healthcare 
professionals were aware of recent ChAdOx1 nCoV-19 
vaccination). The fifth analysis tested the completeness 
of the data, and the sixth analysis was done to have 
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comparable time periods and priority groups for the 
two vaccines.
Assessing the self-controlled case series 
assumptions
To further assess the assumptions of the self-controlled 
case series and our modelling choices, we visually 
examined the data. We plotted a histogram of the 
number of occurrences of an event by time before 
or since vaccination for each outcome to assess the 
possibility that a hospital admission for that event 
might affect subsequent vaccination (supplementary 
fig 2a). We plotted a histogram of the time from event 
to actual end of observation in patients who were 
censored and uncensored to assess if event dependent 
observation periods could be a problem for the analysis 
(supplementary fig 2b).
Event dependent exposures—supplementary figure 
2a shows the number of occurrences of an event by time 
before or after vaccination. We observed a decrease in 
the 28 days immediately before vaccination, indicating 
that occurrence of an event might have reduced the 
likelihood of vaccination. This pattern is similar for 
most of the outcomes and for both vaccines. Therefore, 
we have added the pre-risk period of 28 days.
Event dependent observation periods—supplementary 
figure 2b shows the frequency of days from event to 
actual end of observation in censored and uncensored 
patients. A spike close to zero is apparent in the 
censored data histogram for most of the outcomes, 
excluding CVST. This finding indicates the presence 
of event dependent observation periods (censoring on 
death date due to outcome), which we tested further 
with the first and second sensitivity analyses (excluding 
those who died from the outcome; restricting analysis 
to the period after vaccination, without censoring at 
death). These additional analyses agreed with the 
main analysis, suggesting that there should be little 
concern about these outcomes.
Absolute measure of risk
In self-controlled case series analysis, results are 
presented in relative terms—the ratio of the incidence 
in the exposure risk periods relative to the incidence 
in control periods. We supplemented these results 
with measures of effect of each exposure in absolute 
terms using a method developed to estimate the 
number of exposures needed to produce one excess 
adverse outcome and the excess number of events 
per 10 million exposed for each outcome.24 These 
measures were computed for a period of 8-28 days 
after vaccination to remove the healthy vaccinee effect 
seen at 0-7 days after vaccination. To make numbers 
comparable, the same measures were computed for the 
same period after a SARS-CoV-2 positive test.
Negative or positive controls
We examined the associations of exposures with 
coeliac disease as a negative control outcome25 because 
it was not thought to be associated with exposure 
to vaccination or SARS-CoV-2 infection; and with 
anaphylaxis as a positive control outcome because it 
could occur shortly after either vaccine.26
Patient and public involvement
This project is supported by a patient and public 
involvement advisory panel which we thank for its 
continued support and guidance. The input of the 
panel has helped us identify priority questions for 
consideration. PPIE (patient and public involvement 
and engagement) advisers were supportive of the vital 
importance of reporting on thrombosis risks associated 
with vaccination against covid-19 and covid-19 itself. 
We have reviewed the findings of this study with our 
PPIE advisers. A lay summary has been developed with 
patient and public involvement input and feedback, 
including an infographic.
Results
Table 1 shows the characteristics of 19 608 008 people 
who had the ChAdOx1 nCoV-19 vaccine, 9 513 625 
who had the BNT162b2 mRNA vaccine, and 1 758 095 
with a SARS-CoV-2 positive test. During the study 
period, among those vaccinated, 9764 people had a 
hospital admission related to thrombocytopenia (52 
deaths) and 23 390 people were admitted to hospital 
with venous thromboembolism (1871 deaths); this 
included 119 people with CVST related hospital 
admissions (no deaths). Hospital admission related 
to arterial thromboembolic events occurred in 89 321 
people (6533 deaths); these included 28 222 ischaemic 
strokes (4204 deaths), 62 699 with myocardial 
infarction (2875 deaths), and 3655 with other rare 
arterial thrombotic events (84 deaths). Table 2 shows 
the demographic characteristics of patients who 
experienced the primary outcomes of interest in the 
28 days after exposure. Supplementary table 2 shows 
corresponding results for the secondary outcomes.
Table 3 and figure 1 show the number of patients 
with outcome events in each time period and the 
incidence rate ratios for outcomes in the risk periods 
immediately before and after each exposure.
Primary outcomes
Thrombocytopenia—an increased risk was observed 
at 8-14 days after the ChAdOx1 nCoV-19 vaccine 
(incidence rate ratio 1.33, 95% confidence interval 
1.19 to 1.47) and at 22-28 days (1.26, 1.13 to 1.42). 
An increased risk was also found after a positive SARS-
CoV-2 test (1-7 days: 14.04, 12.08 to 16.31; 8-14 days: 
5.27, 4.34 to 6.40; 15-21 days: 1.91, 1.44 to 2.54; 22-
28 days: 1.50, 1.10 to 2.05).
Venous thromboembolism—an increased risk was 
found at 8-14 days after the ChAdOx1 nCoV-19 vaccine 
(incidence rate ratio 1.10, 95% confidence interval 
1.02 to 1.18) and after a positive SARS-CoV-2 test (1-7 
days: 13.78, 12.66 to 14.99; 8-14 days: 13.86, 12.76 
to 15.05; 15-21 days: 7.88, 7.18 to 8.64; 22-28 days: 
3.38, 3.00 to 3.81).
Arterial thromboembolism—we observed an 
association at 15-21 days after the BNT162b2 mRNA 
vaccine (incidence rate ratio 1.06, 95% confidence 
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interval 1.01 to 1.10) and in those with SARS-CoV-2 
infection (1-7 days: 6.55, 6.12 to 7.02; 8-14 days: 
4.52, 4.19 to 4.88; 15-21 days: 2.02, 1.82 to 2.24; 22-
28 days: 1.26, 1.11 to 1.43).
Secondary outcomes
CVST—we found an increased risk at 8-14 days after 
the ChAdOx1 nCoV-19 vaccine (incidence rate ratio 
4.01, 95% confidence interval 2.08 to 7.71), and at 
15-21 days after the BNT162b2 mRNA vaccine (3.58, 
1.39 to 9.27). CVST was also associated with a positive 
SARS-CoV-2 test (1-7 days: 12.90, 1.86 to 89.64; 8-14 
days: 13.43, 1.99 to 90.59).
Ischaemic stroke—an increased risk was found at 15-
21 days after the BNT162b2 mRNA vaccine (incidence 
rate ratio 1.12, 95% confidence interval 1.04 to 1.20) 
and after a positive SARS-CoV-2 test (1-7 days: 3.94, 
3.46 to 4.47; 8-14 days: 3.25, 2.83 to 3.72; 15-21 days: 
2.00, 1.70 to 2.35; 22-28 days: 1.26, 1.04 to 1.53).
Myocardial infarction—no association was found 
with the ChAdOx1 nCoV-19 or the BNT162b2 mRNA 
vaccine. We found an increased risk of myocardial 
infarction after a positive SARS-CoV-2 test (1-7 days: 
incidence rate ratio 7.95, 95% confidence interval 
7.32 to 8.63; 8-14 days: 4.94, 4.50 to 5.43; 15-21 
days: 1.95, 1.71 to 2.22).
Other rare arterial thrombotic events—an increased 
risk was observed after the ChAdOx1 nCoV-19 vaccine 
at 8-14 days (incidence rate ratio 1.21, 95% confidence 
interval 1.02 to 1.43) and after a positive SARS-CoV-2 
test (1-7 days: 5.35, 3.90 to 7.32; 8-14 days: 5.61, 4.13 
to 7.61; 15-21 days: 2.97, 2.03 to 4.36; 22-28 days: 
2.66, 1.79 to 3.94).
Co-occurrences of thrombocytopenia and venous 
thromboembolism, and of thrombocytopenia and 
arterial thromboembolism 
We investigated the risk of hospital admission or death 
from co-occurrence of thrombocytopenia and venous 
thromboembolism and of thrombocytopenia and 
arterial thromboembolism in the same people before 
and after the ChAdOx1 nCoV-19 or BNT162b2 mRNA 
vaccine within our study period. In the study period, 
3606 patients were admitted to hospital for both 
thrombocytopenia and venous thromboembolism. 
Of these patients, 36 were admitted on the same 
day for both outcomes, while 1628 were first 
admitted for thrombocytopenia and subsequently 
for venous thromboembolism (interquartile range 
for the difference in admissions 16-58 days). We 
found an increased incidence of co-occurrence of 
thrombocytopenia and venous thromboembolism 
Table 1 | Baseline demographic characteristics of people receiving first dose of covid-19 vaccine or testing positive for SARS-CoV-2 virus among 
vaccinated population in England from 1 December 2020 to 24 April 2021. Figures are column % (number) unless stated otherwise
Characteristics ChAdOx1 nCoV-19 vaccine BNT162b2 mRNA vaccine Positive SARS-CoV-2 test (among vaccinated population)
Total No of people 19 608 008 9 513 625 1 758 095
Sex
 Women 50.1 (9 822 236) 57.2 (5 443 631) 56.7 (996 462)
 Men 45.1 (8 848 683) 40.0 (3 808 484) 40.0 (703 381)
 Not recorded 4.8 (937 088) 2.7 (261 510) 3.3 (58 252)
Mean age, years (SD) 55.5 (14.9) 61.5 (18.8) 51.7 (17.0)
Age group, years
 16-29 5.4 (1 060 982) 7.2 (685 100) 10.9 (191 741)
 30-39 7.9 (1 551 528) 8.3 (786 815) 12.6 (220 712)
 40-49 19.4 (3 803 176) 10.8 (1 030 833) 20.9 (367 869)
 50-59 28.4 (5 564 739) 15.6 (1 486 062) 26.7 (469 206)
 60-69 20.3 (3 988 397) 17.8 (1 692 935) 14.4 (252 849)
 70-79 14.2 (2 782 590) 20.3 (1 934 771) 7.2 (126 296)
 80-89 3.3 (643 058) 17.0 (1 619 781) 5.1 (90 261)
 ≥90 1.1 (213 537) 2.9 (277 328) 2.2 (39 161)
Ethnicity
 White 72.9 (14 298 075) 77.4 (7 367 723) 71.3 (1 253 446)
 Indian 2.2 (425 195) 2.5 (239 326) 3.9 (69 356)
 Pakistani 1.3 (256 270) 1.0 (97 066) 2.8 (49 689)
 Bangladeshi 0.6 (109 817) 0.4 (36 488) 1.1 (19 698)
 Other Asian 1.0 (192 997) 1.1 (102 139) 1.7 (30 082)
 Black Caribbean 0.6 (120 296) 0.6 (53 076) 0.7 (12 732)
 Black African 1.1 (213 931) 1.0 (91 527) 1.6 (28 592)
 Chinese 0.4 (69 563) 0.3 (26 228) 0.2 (3553)
 Other ethnic group 1.9 (364 117) 1.7 (157 233) 2.5 (43 879)
 Ethnicity not recorded 18.1 (3 557 746) 14.1 (1 342 819) 14.1 (247 068)
Previous conditions
 Previous thrombocytopenia 0.1 (25 917) 0.2 (18 004) 0.3 (4543)
 Previous arterial thromboembolism 1.5 (294 698) 2.7 (254 295) 2.4 (41 821)
 Myocardial infarction 1.2 (227 594) 2.1 (201 610) 1.8 (31 566)
 Ischaemic stroke 0.3 (68 124) 0.6 (53 982) 0.6 (10 783)
 Other rare arterial thrombosis 0.0 (9671) 0.1 (6727) 0.1 (1515)
 Previous venous thromboembolism 0.2 (42 247) 0.3 (29 173) 0.5 (8671)
 Previous CVST 0.0 (280) 0.0 (155) 0.0 (30)
BNT162b2 mRNA=Pfizer-BioNTech; CVST=cerebral venous sinus thrombosis; ChAdOx1 nCoV-19=Oxford-AstraZeneca vaccine.
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within 8-14 days of the ChAdOx1 nCoV-19 vaccine 
(incidence rate ratio 1.34, 95% confidence interval 
0.99 to 1.83). No association was found with the 
BNT162b2 mRNA vaccine, however we observed a 
positive association with SARS-CoV-2 infection (1-7 
days: 4.91, 3.50 to 6.89; 8-14 days: 1.91, 1.20 to 3.06; 
supplementary table 3).
In the study period, 2112 patients were admitted 
to hospital for both thrombocytopenia and arterial 
thromboembolism. Of these patients, 20 were admitted 
on the same day for both outcomes, while 1097 were 
first admitted for thrombocytopenia and subsequently 
for arterial thromboembolism (interquartile range for 
the difference in admissions 18-65 days). We found no 
association with the ChAdOx1 nCoV-19 vaccine. We 
found a possible signal for the BNT162b2 vaccine at 
8-14 days (incidence rate ratio 1.40, 95% confidence 
interval 0.97 to 2.01) and a positive association with 
the SARS-CoV-2 infection (1-7 days: 3.69, 2.29 to 6.05; 
8-14 days: 2.59, 1.47 to 4.62; supplementary table 3).
Subgroup analyses by age group and sex
Supplementary tables 4a and 4b show the incidence 
rate ratios for subgroup analyses by age group or sex. 
An increased risk of thrombocytopenia was observed 
in people who had the ChAdOx1 nCoV-19 vaccine who 
were younger than 50 years (8-14 days: incidence rate 
ratio 1.56, 95% confidence interval 1.20 to 2.02; 22-
28 days: 1.40, 1.04 to 1.88) and older than 50 years (8-
14 days: 1.27, 1.13 to 1.43; 22-28 days: 1.22, 1.08 to 
1.39). An increased risk of venous thromboembolism 
was observed in those who had the ChAdOx1 nCoV-19 
vaccine who were older than 50 years (8-14 days: 1.09, 
1.01 to 1.18) with a similar increase in those younger 
than 50 (1.19, 0.96 to 1.48). An increased risk of CVST 
was observed in those who had the ChAdOx1 nCoV-19 
vaccine who were younger than 50 (8-14 days: 6.36, 
2.61 to 15.46), and no significant increased risk was 
found in those older than 50 years. An increased risk 
of other rare arterial thrombosis was observed in those 
who had the ChAdOx1 nCoV-19 vaccine who were 
younger than 50 (8-14 days: 1.20, 1.01 to 1.44).
Negative or positive control outcomes
We found no increased risk in those with coeliac disease 
(negative control) across the prespecified time periods 
for the vaccine exposures. Anaphylaxis (positive 
control) showed the expected increased risk in the 
initial period after exposure for both vaccinations but 
not in later periods (supplementary table 5).
Incidence rates
The background incidence rates per 100 000 
person years for thrombocytopenia and arterial 
thromboembolism were higher in men while rates 
for venous thromboembolism tended to be higher in 
Table 2 | Demographic characteristics of patients who experienced outcome in 28 days after first dose of covid-19 vaccine or SARS-CoV-2 infection 
among vaccinated population in England from 1 December 2020 to 24 April 2021. Figures are column % (number) unless stated otherwise
Characteristics






















Total No of people with 
event 1480 1010 950 3077 2054 4671 11 617 9473 4076
Sex
 Women 47.8 (707) 43.5 (439) 39.5 (375) 52.2 (1605) 50.7 (1041) 38.4 (1795) 39.3 (4563) 39.3 (3719) 34.8 (1418)
 Men 52.2 (773) 56.5 (571) 60.5 (575) 47.5 (1462) 49.2 (1011) 61.6 (2876) 60.6 (7044) 60.7 (5749) 65.2 (2658)
 Not recorded 0 0 0 0.3 (10) 0.1 (<5) 0 0.1 (10) 0.1 (5) 0
Mean age (SD) 66.3 (16.0) 73.1 (15.5) 67.9 (16.0) 68.8 (14.7) 73.5 (13.8) 63.8 (14.8) 72.2 (12.5) 76.7 (11.7) 72.2 (13.5)
Age group, years
 16-29 2.5 (37) 1.7 (17) 1.8 (17) 1.8 (54) 1.1 (22) 1.3 (60) 0.1 (14) 0.1 (5) *
 30-39 4.7 (69) 3.0 (30) 4.0 (38) 2.8 (87) 1.5 (30) 4.3 (199) 0.6 (66) 0.3 (32) <30
 40-49 7.7 (114) 4.7 (47) 7.2 (68) 5.0 (153) 3.7 (77) 10.3 (482) 2.7 (314) 1.6 (155) 4.5 (182)
 50-59 15.3 (227) 7.6 (77) 16.7 (159) 13.8 (424) 9.7 (199) 24.2 (1131) 13.0 (1512) 7.7 (729) 14.3 (583)
 60-69 22.9 (339) 15.0 (152) 20.3 (193) 22.4 (689) 15.1 (310) 23.6 (1102) 23.1 (2680) 15.2 (1437) 21.7 (886)
 70-79 26.1 (387) 24.6 (248) 22.4 (213) 32.1 (987) 28.7 (590) 20.5 (959) 33.3 (3871) 26.5 (2507) 24.8 (1010)
 80-89 14.9 (220) 35.6 (360) 21.1 (200) 16.3 (501) 33.0 (677) 12.4 (580) 18.0 (2090) 37.9 (3592) 24.3 (992)
 ≥90 5.9 (87) 7.8 (79) 6.5 (62) 5.9 (182) 7.3 (149) 3.4 (158) 9.2 (1070) 10.7 (1016) 9.7 (394)
Ethnicity
 White 89.3 (1321) 89.3 (902) 83.2 (790) 90.3 (2777) 89.9 (1847) 76.2 (3558) 88.7 (10 310) 89.5 (8483) 80.4 (3279)
 Indian 2.4 (35) 1.8 (18) 2.9 (28) 1.2 (38) 1.3 (27) 3.5 (163) 2.4 (279) 2.5 (233) 4.3 (174)
 Pakistani 0.9 (13) 1.2 (12) 3.1 (29) 0.6 (17) 0.7 (15) 2.4 (113) 1.6 (184) 1.3 (121) 4.0 (163)
 Bangladeshi 0.5 (7) <10 1.3 (12) 0.3 (8) * 1.3 (59) 0.4 (46) 0.3 (29) 1.4 (59)
 Other Asian 0.8 (12) 1.0 (10) 1.6 (15) 0.3 (8) 0.8 (16) 1.8 (84) 0.6 (71) 0.6 (55) 1.7 (69)
 Black Caribbean 0.9 (13) 0.6 (6) 1.1 (10) 1.3 (39) 0.8 (16) 2.6 (121) 0.7 (79) 0.5 (49) 1.1 (43)
 Black African 0.9 (13) 0.5 (5) 1.6 (15) 0.7 (23) 1.0 (20) 3.1 (143) 0.5 (60) 0.4 (40) 1.0 (41)
 Chinese * * * * * 0.2 (10) 0.1 (16) 0.1 (13) 0.3 (12)
 Other ethnic group 1.2 (18) 1.2 (12) 2.2 (21) 1.0 (32) 1.0 (21) 3.4 (158) 1.1 (122) 1.0 (93) 2.5 (103)
 Ethnicity not 
recorded 3.2 (47) 3.7 (37) 2.9 (28) 4.3 (132) 4.3 (88) 5.6 (262) 3.9 (450) 3.8 (357) 3.3 (133)
BNT162b2 mRNA=Pfizer-BioNTech vaccine; ChAdOx1 nCoV-19=Oxford-AstraZeneca vaccine.
*Cells with numbers <5 are suppressed.
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Table 3 | Incidence rate ratios (95% confidence intervals) for primary composite and secondary outcomes in predefined 
risk periods immediately before and after exposure to vaccine and before and after positive SARS-CoV-2 test result, 
adjusted for calendar time from 1 December 2020 to 24 April 2021
Outcome and time period
ChAdOx1 nCoV-19 vaccine BNT162b2 mRNA vaccine Positive SARS-CoV-2 test
No of 
events












 Baseline 3851 1.00 2009 1.00 381 1.00
 −28 to −1 days 910 0.67 (0.62 to 0.72) 504 0.63 (0.56 to 0.69) 430 4.71 (4.06 to 5.47)
 0 day 19 0.39 (0.25 to 0.62) 13 0.41 (0.23 to 0.70) 299 75.77 (64.48 to 89.03)
 1-7 days 331 0.97 (0.87 to 1.10) 243 1.02 (0.89 to 1.18) 398 14.04 (12.08 to 16.31)
 8-14 days 438 1.33 (1.19 to 1.47) 254 1.02 (0.89 to 1.17) 152 5.27 (4.34 to 6.40)
 15-21 days 337 1.08 (0.96 to 1.22) 259 1.06 (0.93 to 1.22) 56 1.91 (1.44 to 2.54)
 22-28 days 356 1.26 (1.13 to 1.42) 241 1.08 (0.94 to 1.23) 45 1.50 (1.10 to 2.05)
Venous thromboembolism
 Baseline 9846 1.00 4627 1.00 1211 1.00
 −28 to −1 days 2561 0.69 (0.66 to 0.73) 1224 0.64 (0.60 to 0.68) 1007 3.43 (3.14 to 3.76)
 0 day 53 0.46 (0.35 to 0.60) 25 0.35 (0.24 to 0.52) 833 63.52 (57.80 to 69.80)
 1-7 days 746 0.92 (0.85 to 1.00) 486 0.92 (0.83 to 1.01) 1305 13.78 (12.66 to 14.99)
 8-14 days 870 1.10 (1.02 to 1.18) 555 0.99 (0.90 to 1.08) 1371 13.86 (12.76 to 15.05)
 15-21 days 763 1.03 (0.96 to 1.12) 514 0.91 (0.82 to 1.00) 807 7.88 (7.18 to 8.64)
 22-28 days 645 0.97 (0.89 to 1.06) 474 0.89 (0.81 to 0.99) 355 3.38 (3.00 to 3.81)
Arterial thromboembolism
 Baseline 31 944 1.00 21 147 1.00 2743 1.00
 −28 to −1 days 9155 0.78 (0.76 to 0.80) 5984 0.71 (0.69 to 0.73) 3054 4.59 (4.34 to 4.86)
 0 day 143 0.33 (0.28 to 0.39) 125 0.38 (0.32 to 0.45) 1165 42.26 (39.33 to 45.40)
 1-7 days 2769 0.92 (0.88 to 0.95) 2161 0.92 (0.88 to 0.96) 1290 6.55 (6.12 to 7.02)
 8-14 days 3065 1.02 (0.98 to 1.06) 2377 0.98 (0.94 to 1.02) 917 4.52 (4.19 to 4.88)
 15-21 days 2906 1.01 (0.97 to 1.05) 2590 1.06 (1.01 to 1.10) 426 2.02 (1.82 to 2.24)
 22-28 days 2734 1.02 (0.98 to 1.06) 2221 0.95 (0.91 to 0.99) 278 1.26 (1.11 to 1.43)
Secondary outcomes
Cerebral venous sinus thrombosis
 Baseline 44 1.00 21 1.00 * 1.00
 −28 to −1 days 9 0.59 (0.27 to 1.25) 7 1.04 (0.43 to 2.51) * 2.40 (0.22 to 25.98)
 0 day * 1.95 (0.26 to 14.48) * NA * 115.70 (16.48 to 812.29)
 1-7 days * 0.51 (0.12 to 2.19) * NA * 12.90 (1.86 to 89.64)
 8-14 days 15 4.01 (2.08 to 7.71) * 2.57 (0.85 to 7.78) * 13.43 (1.99 to 90.59)
 15-21 days 8 2.15 (0.96 to 4.85) 6 3.58 (1.39 to 9.27) * 6.33 (0.63 to 63.67)
 22-28 days * 0.60 (0.14 to 2.55) * NA * 5.81 (0.59 to 57.24)
Ischaemic stroke
 Baseline 10 355 1.00 6439 1.00 1069 1.00
 −28 to −1 days 2671 0.67 (0.64 to 0.70) 1614 0.62 (0.58 to 0.65) 1128 4.21 (3.84 to 4.61)
 0 day 43 0.29 (0.22 to 0.40) 33 0.32 (0.23 to 0.45) 273 23.55 (20.53 to 27.01)
 1-7 days 968 0.94 (0.88 to 1.01) 718 0.97 (0.89 to 1.05) 326 3.94 (3.46 to 4.47)
 8-14 days 1080 1.07 (1.00 to 1.14) 789 1.03 (0.95 to 1.11) 275 3.25 (2.83 to 3.72)
 15-21 days 965 1.00 (0.93 to 1.07) 862 1.12 (1.04 to 1.20) 174 2.00 (1.70 to 2.35)
 22-28 days 920 1.02 (0.95 to 1.10) 765 1.03 (0.96 to 1.12) 112 1.26 (1.04 to 1.53)
Myocardial infarction
 Baseline 22 079 1.00 15 124 1.00 1776 1.00
 −28 to −1 days 6565 0.83 (0.81 to 0.86) 4485 0.76 (0.73 to 0.78) 1995 4.74 (4.42 to 5.08)
 0 day 103 0.36 (0.29 to 0.43) 95 0.41 (0.33 to 0.50) 906 53.06 (48.77 to 57.73)
 1-7 days 1881 0.92 (0.87 to 0.96) 1483 0.90 (0.85 to 0.95) 970 7.95 (7.32 to 8.63)
 8-14 days 2028 0.99 (0.95 to 1.04) 1668 0.98 (0.93 to 1.03) 624 4.94 (4.50 to 5.43)
 15-21 days 2000 1.02 (0.97 to 1.07) 1789 1.04 (0.99 to 1.09) 258 1.95 (1.71 to 2.22)
 22-28 days 1889 1.02 (0.97 to 1.07) 1510 0.92 (0.87 to 0.97) 161 1.15 (0.97 to 1.35)
Other rare arterial thrombosis
 Baseline 1469 1.00 732 1.00 139 1.00
 −28 to −1 days 365 0.63 (0.56 to 0.71) 183 0.59 (0.50 to 0.70) 164 4.70 (3.68 to 6.02)
 0 day 5 0.25 (0.10 to 0.59) * 0.08 (0.01 to 0.56) 55 35.15 (25.40 to 48.65)
 1-7 days 105 0.74 (0.60 to 0.91) 93 1.03 (0.82 to 1.29) 60 5.35 (3.90 to 7.32)
 8-14 days 164 1.21 (1.02 to 1.43) 88 0.95 (0.75 to 1.19) 65 5.61 (4.13 to 7.61)
 15-21 days 127 1.00 (0.83 to 1.21) 107 1.16 (0.94 to 1.44) 34 2.97 (2.03 to 4.36)
 22-28 days 114 1.00 (0.81 to 1.22) 102 1.15 (0.93 to 1.42) 31 2.66 (1.79 to 3.94)
BNT162b2 mRNA=Pfizer-BioNTech vaccine; ChAdOx1 nCoV-19=Oxford-AstraZeneca vaccine.
*Cells with entries <5 are suppressed.
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women (supplementary tables 6a and 6b). Rates of all 
outcomes increased with age except for CVST where 
the highest rates occurred in those aged 20-50 years 
and 60-64 years. Rates also varied by ethnicity.
Sensitivity analyses
Sensitivity analyses 1 and 2 were generally consistent 
with the main analysis. This finding suggests the 
results were not sensitive to censoring due to death, 
except for reductions in incidence rate ratios for 
arterial thromboembolism and ischaemic stroke 
associated with the BNT162b2 mRNA vaccine at 
15-21 days and CVST associated with both vaccines 
for sensitivity analysis 2. Estimates from sensitivity 
analyses 3-5 were consistent with the main analysis 
for all outcomes, although confidence intervals were 
wider due to smaller numbers, particularly for CVST 
(supplementary tables 7a-c and supplementary fig 
3a and 3b). Estimates from sensitivity analysis 6 are 
consistent with the main results for the ChAdOx1 
nCoV-19 vaccine, while they decreased slightly for the 
BNT162b2 mRNA vaccine, but stayed significant for 
CVST.
Absolute measures of effect of vaccinations and 
SARS-CoV-2 infection
We estimated the number of exposures needed for 
one excess event and the excess number of events 



















































































































































































































Fig 1 | Incidence rate ratios (95% confidence intervals) for outcomes in predefined risk periods immediately before and after exposure to ChAdOx1 
nCoV-19 (Oxford-AstraZeneca) or BNT162b2 mRNA (Pfizer-BioNTech) vaccine, and before and after a positive SARS-CoV-2 test result from 1 December 
2020 to 24 April 2021. CVST=cerebral venous sinus thrombosis
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per 10 million exposed to each vaccine or with a 
SARS-CoV-2 positive test (supplementary table 8). 
For example, with the ChAdOx1 nCoV-19 vaccine the 
excess events were 107 for thrombocytopenia, 66 
for venous thromboembolism, and seven for CVST. 
For the BNT1262b2 mRNA vaccine, there are an 
estimated 143 extra cases of ischaemic stroke. For 
SARS-Cov-2 infection, there are an estimated 934 
extra cases of thrombocytopenia, 12 614 of venous 
thromboembolism, 1699 of ischaemic stroke, and 20 
of CVST.
Discussion
Our analysis of serious adverse events leading to 
hospital admission or death, covering a population of 
over 29 million vaccinated people in England, showed 
increased relative incidences of thrombocytopenia 
and venous thromboembolism in the 8-14 days 
after ChAdOx1 nCoV-19 vaccination but not of 
arterial thromboembolism. Conversely, BNT162b2 
mRNA vaccination was associated with arterial 
thromboembolism 15-21 days after vaccination but not 
with thrombocytopenia or venous thromboembolism. 
For our prespecified secondary outcomes, we found 
an increased risk of CVST and other rare arterial 
thrombotic events at 8-14 days after the ChAdOx1 
nCoV-19 vaccination. We also found an increased 
risk of CVST and ischaemic stroke at 15-21 days after 
vaccination with BNT162b2 mRNA. The increased risks 
for CVST for both vaccines might be a potential signal, 
although numbers were small and further confirmation 
is needed. The small absolute risks associated with 
both of the vaccines should be noted; for instance, for 
10 million people exposed to the ChAdOx1 nCoV-19 
vaccine, there were seven excess events of CVST in the 
28 days after the vaccine.
The subgroup analysis by age group has shown no 
association between CVST and the BNT162b2 mRNA 
vaccine, but a strong association with ChAdOx1 nCoV-
19 in those younger than 50 years old (incidence rate 
ratio 6.36, 95% confidence interval 2.61 to 15.46). 
However, the sample size was considerably lower in 
the subgroup analyses, especially for the BNT162b2 
mRNA vaccine (fewer than five people in each risk 
interval). However, the point estimate of incidence rate 
ratio associated with the BNT162b2 mRNA vaccine 
remained large (3.90, 0.96 to 15.82 at 15-21 days), 
suggesting a signal for CVST after vaccination.
The results were robust to sensitivity analyses, except 
for the association between the BNT162b2 mRNA 
vaccine and arterial thromboembolism (including 
ischaemic stroke), which reduced in magnitude in the 
sensitivity analyses accounting for fatal events. Also, 
we observed some variation in results for the CVST 
outcome; for example, the incidence rate ratios for 
the second sensitivity analysis were lower compared 
with the main analysis, which might be due to small 
numbers and wider confidence intervals. The incidence 
rate ratios associated with SARS-CoV-2 infection were 
much higher for each outcome than those associated 
with either vaccine, with the greatest risk for all 
outcomes being in the first week after a positive test.
Strengths and limitations of this study
Analyses of safety signals are complex, especially in 
the context of a new disease for which the effects could 
be similar to adverse events of a vaccine deployed to 
prevent it. Furthermore, the vaccination programme in 
England began during the third pandemic wave, which 
coincided with the emergence of the B.1.1.7 variant of 
concern. In this context, case-control or cohort studies 
are probably subject to major confounding, especially 
given the pace of vaccination where matched 
unvaccinated controls might only be unexposed 
for relatively short periods before vaccination (or 
uninfected patients before SARS-CoV-2 infection). For 
this reason, we used the self-controlled case series 
study design, which has major advantages because 
the within-person comparison reduces potential 
confounding for all fixed characteristics. Our inclusion 
of calendar time in weekly blocks further accounted 
for temporal confounding, important given the time 
varying influence of pandemic waves on health and 
healthcare systems. To provide greater confidence in 
assessing associations between vaccine and outcome, 
we conducted our analyses on negative (coeliac) and 
positive (anaphylaxis) control outcomes.
The UK provides an ideal setting to study these 
widely deployed vaccines because they have been 
used at scale, enabling direct comparison. Other 
strengths of our study include representativeness, data 
completeness for exposures, and timeliness. Our results 
are likely to be generalisable to other older populations 
because we have studied a very large sample of much 
more diverse patients than those enrolled in clinical 
trials12; however, they might not be generalisable to 
younger populations because they have not yet been 
vaccinated in large numbers. Unlike signals arising 
from case report series,7 8 our study is not subject to 
recall selection biases because we used prospectively 
recorded medical data collected during the course of 
NHS clinical care. We obtained data from four, high 
quality, national electronic health record databases, all 
used for operational purposes. Our sensitivity analyses 
generally support our interpretations. To estimate 
associations with SARS-CoV-2 infection, we used 
people who had been vaccinated and accounted for 
time varying effects of vaccination and infection in the 
same model. We have also published our scientifically 
reviewed protocol.15
Our study is limited by restricting our analysis to 
first vaccine dose only (which is necessary since these 
analyses are being undertaken during the vaccination 
roll-out), lack of formal adjudication of routinely 
acquired outcomes, and potential for misclassification 
of outcomes or exposures. While we captured 
completed hospital admissions, we did not capture 
admissions where patients were still in hospital by 
the study end date. However, we believe that any bias, 
if present, is probably non-differential with respect 
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to each vaccine, and so the comparisons between 
vaccines are unlikely to be affected.
Comparison with other studies
The European Medicines Agency reported at least 
169 possible cases of CVST and 53 possible cases 
of splanchnic vein thrombosis among 34 million 
recipients of the ChAdOx1 nCoV-19 vaccine; 35 
possible cases of central nervous system thrombosis 
among 54 million recipients of the Pfizer-BioNTech 
mRNA vaccine; and five possible (but unvetted) cases 
of CVST among 4 million recipients of the Moderna 
mRNA vaccine. A recent study has estimated rate ratios 
for thromboembolic events after vaccination by using a 
case-control and a self-controlled case series analysis 
with national Scottish data.27 The authors found that 
the rate ratios estimated from the nested case-control 
study were larger than those estimated using the self-
controlled case series analysis. This finding might 
indicate the presence of residual confounding or 
confounding by indication, which the self-controlled 
case series analysis takes naturally into account. 
Overall, their study showed broadly similar results to 
ours for the ChAdOx1 nCoV-19 vaccine: an increased 
risk of thrombocytopenia (Scottish results from self-
controlled case series (0-28 days): incidence rate 
ratio 1.98, 95% confidence interval 1.29 to 3.02; our 
study (8-28 days): 1.23, 1.14 to 1.33) but not arterial 
thromboembolic events (0.97, 0.93 to 1.02, and 
1.08, 0.95 to 1.22, respectively). The authors did not 
find an association between these outcomes and the 
BNT162b2 mRNA vaccine, as we have found. These 
differences might be explained by the smaller numbers 
in the Scottish population (0.8 million vaccinated in 
Scottish study with BNT162b2 mRNA compared with 
9.5 million in England in our study).
Policy implications
The increased risk of thrombocytopenia with 
ChAdOx1 nCoV-19 and the increased risk of arterial 
and venous events identified with both vaccines has 
major implications for healthcare policy and further 
research. However, these findings would benefit 
from corroboration from other countries using 
similarly robust analytical approaches and large 
datasets. We have highlighted the results of the 
statistically significant findings, although further 
consideration of the clinical significance of these 
results is needed, particularly when the estimates 
are close to one.
Conclusions
We found an increased risk of thrombocytopenia, 
venous thromboembolism, and other rare arterial 
thrombotic events in short time intervals after a first 
dose of the ChAdOx1 nCoV-19 vaccine, and of arterial 
thromboembolism and ischaemic stroke after a first 
dose of the BNT162b2 mRNA vaccine. An increased 
risk of CVST was found after a first dose of both 
vaccines, which might be a potential signal, although 
numbers were small and further confirmation is 
needed. Importantly, the risks of these outcomes after 
vaccination were much lower than those associated 
with SARS-CoV-2 infection in the same population.
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